Mahmoud is a Principal Investigator within the Translational Lab in Genetic Medicine (TLGM) at the Agency for Science, Technology, and Research (A*STAR). He is also an Assistant Professor at the Department of Medicine, the National University of Singapore (NUS), and the Associate Director of TLGM.
Amberlyn is in charge of our animal colony management, and is also assisting with our preclinical therapeutic studies.
Kagistia is developing human stem cell-based experimental systems aimed at identifying and validating therapeutic targets for Huntington disease and Fragile X Syndrome.
Costanza is a SINGA scholar investigating white matter pathology in Huntington disease. Using behavioural and neuropathological analysis of rodent models of HD, her PhD studies aim to examine the aetiology and consequences of oligodendroglial pathology in HD.
Jinqiu is developing forward genetic screens in human Huntington disease neural cells that aim to uncover the determinants of selective neuronal vulnerability in HD. She is also leading our stem cell-based disease modeling efforts using cerebral organoids.
Harwin is leading projects focused on developing zebrafish models of Huntington disease, and in particular the white matter abnormalities and myelination deficits.
Ruizhu is spearheading projects investigating the role of neuro-inflammatory processes in Huntington disease using human stem cell and rodent-based experimental systems.
Amin is a SINGA scholar in the first year of PhD studies. His project focuses on discovering and modeling genetic forms of white matter disease.
Amirah is assisting with a number of Huntington disease animal studies and in particular assessments of neuropathological measures in our therapeutic studies.
Georgia is a SINGA scholar studying Fragile X Syndrome (FXS). Using isogenic pluripotent stem cell-derived human neurons, her PhD studies aim to delineate pathogenic mechanisms contributing to neuronal dysfunction in FXS.
Bernice oversaw our cloning efforts for a range of genome engineering projects. She was also in charge of lab management.
Roy led studies focused on characterization myelination abnormalities and white matter plasticity deficits in animal models of Huntington disease.
Yihui was a research officer (2012-2016) assisting with a range of Huntington disease projects.
Jolene led a number of projects focused to deciphering HTT CAG repeat length effects in Huntington disease using isogenic human stem cells and unbiased omics analyses.
Yi Lin was investigating the pathogenic mechanisms underlying myelination deficits and white matter pathology in Huntington disease. She also worked on developing novel approaches to silence HTT.
Marta spearheaded our in vivo target validation and preclinical therapeutic studies using behavioural and neuropathological assessments of rodent models of HD.
Xiaohong was leading projects focused on validation of putative therapeutic targets in human neurons using TALEN and CRISPR-based genome editing and directed neuronal differentiation of HD patient hiPSCs.
Carola was an ARAP PhD Scholar. Her studies focussed on evaluating white matter plasticity in response to environmental factors in Huntington disease. She successfully defended her PhD in 2017.
Qiyu assisted with our genome engineering and human stem cell-based disease modeling projects. She moved to the Weizmann Institute of Science to start PhD studies in 2017.
Bryan assisted with our target validation studies using neurons differentiated from human stem cells. He moved to the University of Oxford to start PhD studies in 2017.